RE: HEY POLAK GMP TTH$32.50 Novo lags behind
Did I mention that NN STILL has NOT brought their GLP1 Analogue Liraglutide through the Clinical Process?? Very UNSUCCESSFUL with this so far!! They are SO Behind!! Byetta bringing in over a $ Billion a Year and Novo still NOTHING!! Nothing.......WTF!!
THIS is WHY Transition terminated the negotiations with Novo!! Then sent Novo a Notice of Termination. Novo wanted to combine TT-223 with Liraglutide for that long awaited GLP1+TT-223 Testing. Why should Transition play catch-up with Novo's GLP1 Analogue?? Answer is "We Don't Have To." "We don't answer to Novo...they answer to US!"
When will it be Approved?? Gosh we could wait 2 or 3 more years for Novo to get their GLP1Analogue approved. Novo proved to be too slow to keep their rights to GLP1+TT-223 and lost it due to Non-Performance. Back to Transition it came. Now the body of evidence points to TT-223 as the go to Analogue in Typell DB for controlling Blood Glucose levels. It is the KEY.
Think Novo wasn't after the Licence Agreement to the Patents for GLP1 in the USA that Transition has??? Thats a laugh!!
Transition has the patents secured for Exclusivity to their Claims and now their Patent Protection extends to Type1 Diabetes Treatment with GLP1 and GLP1+TT-223 in the USA..... .......Not Novo.
Dr. Cruz turned down Novos offer during the GF Negotiations and hasn't looked back since. He started the higher dosing studies to support Phasell Trials TT-223 Waaaaayy Baaaaack in September already.
As a matter of fact it was ONLY 8 WEEKS from the time Novo HAD to give GLP1 back and he was moving forward with GLP1+TT-223 by announcing a $4million Partnership with the Junior Diabetes Research Foundation (or JDRF as they are known) for Trials with GLP1+TT-223 in Type1 DB. 8 WEEKS !!
.............."TORONTO, Mar. 14 - Transition Therapeutics Inc. ("Transition") (TSX: TTH), announced the signing of an exclusive license agreement to a patent portfolio ("Patent Portfolio") for the use of Glucagon-Like Peptide-1 ("GLP-1") analogues in the treatment of Type I diabetes. The Patent Portfolio includes two issued US patents (US No. 6,989,148 & US No. 6,899,883). The claims in these issued US patents cover the use of GLP-1 analogues alone or in combination with insulins for the treatment of Type I diabetes.
The addition of this patent portfolio strengthens the overall intellectual property protection of Transition's GLP1-I.N.T.™ (Now GLP1+TT-223) regenerative product. The license also provides Transition with exclusivity to key claims necessary for GLP-1 analogue therapy to extend to TypeI Diabetes in the United States.
According to Dr. Joseph Gilbert, Vice-President Research, London Health Sciences Centre, Director of London Health Sciences Centre Research Inc. and Chief Administrative Officer at the Lawson Health Research Institute, "We are pleased to be able to license our GLP-1 intellectual property to a company such as Transition Therapeutics Inc." Dr. Gilbert further added, "The existence of emerging Canadian biotechnology companies like Transition play an important function in the movement of early stage discoveries out of the laboratory for the benefit of patients."
Transition signed this exclusive license agreement ("Agreement") to the Patent Portfolio with London Health Sciences Centre Research Inc. ("LHSCRI"). Under the terms of the Agreement, Transition will issue to LHSCRI a number of Transition common shares having a value of $286,000 at a price equal to the weighted average trading price of Transition shares from March 15 - March 21, 2006. In addition, LHSCRI is entitled to receive milestone payments and royalties on amounts actually received by Transition from the net sales of products covered by issued Patent Portfolio claims or the sublicense of the Patent Portfolio."
The arguement that Novo held up Transitions research for years upon years doesn't hold water for me because it is ONLY GLP1+TT-223 Testing in TYPE2 DB that was held up, and THAT is awaiting more results from TT-223 Stand Alone to better understand the DLP for TT-223.......the integral KEY to a sucessful GLP1+TT-223 Phasell in TYPE2 DB.!! THE KEY!!
Type2 DB is 90%-95% of the USA Market @ an estimated $16 BILLION.........Large Market to tap into don't you think??
Novo was dragging us down with GLP1 in Type2 BUT Transition wouldn't be at this rather impressive stage of HUMAN Drug Development without all the testing results that were generated with Novo the last 18 months ( Dr. Cruz highlights the last 12 months in particular, but yes about 18 months).......I restate once again......I am glad Novo is out of the picture. I myself as an Investor would not want to wait for Novo to get caught up in the Incretin Mimetic Game just to wait to move our Technology ahead in a couple more years or three.
It is crystal clear that Transition is in the Drivers Seat getting this technology puzzle put together. Plain and Simple.
........... TT-223 Stand Alone has Better Results than either Byetta OR Liraglutide (Novo's STILL UNAPPROVED GLP1 Analogue STILL) did at this stage of the game. Way better when you take into account the Nausea and vomiting that they both induce in Humans.......whereas TT-223 Does Not have ANY Nausea related adverse events in Humans at all. THATS HUGE !!